📊 TLPH Key Takeaways
Is Talphera, Inc.. (TLPH) a Good Investment?
Talphera is a pre-revenue clinical-stage pharmaceutical company with virtually zero commercial revenue ($28K annually) while burning $11.4M in operating cash flow. With only $5.9M in cash and a 6-month runway at current burn rates, the company faces imminent capital requirement and execution risk without approved products generating meaningful revenue.
Why Buy Talphera, Inc.. Stock? TLPH Key Strengths
- Strong liquidity position with 5.49x current ratio and 5.18x quick ratio
- Conservative leverage with 0.34x debt-to-equity ratio
- Manageable absolute debt levels at $5.8M long-term debt against $17M equity
TLPH Stock Risks: Talphera, Inc.. Investment Risks
- Negligible revenue base of $28K annually with massive -$13.5M operating loss
- Critical cash burn of -$11.4M operating cash flow providing only ~6 month survival runway
- Clinical-stage company with no approved revenue-generating products facing high execution risk
- Negative margins: -48,157% operating margin and -51,035% net margin indicate severe operational distress
- 10 insider Form 4 filings in 90 days suggest potential management instability or significant transactions
Key Metrics to Watch
- Cash runway and timing of next capital raise requirement
- Clinical trial progression and regulatory milestone achievements
- Monthly cash burn rate trends and operating cash flow acceleration toward profitability
- Any revenue inflection from product approvals or partnerships
Talphera, Inc.. (TLPH) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 5.49x current ratio provides a solid financial cushion.
TLPH Profit Margin, ROE & Profitability Analysis
TLPH vs Healthcare Sector: How Talphera, Inc.. Compares
How Talphera, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Talphera, Inc.. Stock Overvalued? TLPH Valuation Analysis 2026
Based on fundamental analysis, Talphera, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Talphera, Inc.. Balance Sheet: TLPH Debt, Cash & Liquidity
TLPH Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Talphera, Inc..'s revenue has declined by 99% over the 5-year period, indicating business contraction. The most recent EPS of $5.72 reflects profitable operations.
TLPH Revenue Growth, EPS Growth & YoY Performance
TLPH Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | -$2.6M | N/A |
| Q2 2025 | N/A | -$2.6M | N/A |
| Q1 2025 | N/A | -$2.6M | $-0.10 |
| Q3 2024 | N/A | -$1.4M | N/A |
| Q2 2024 | N/A | -$3.8M | N/A |
| Q3 2023 | N/A | -$1.4M | $-0.08 |
| Q2 2023 | N/A | -$4.4M | $-0.40 |
| Q3 2022 | $507.0K | -$6.8M | $-0.94 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Talphera, Inc.. Dividends, Buybacks & Capital Allocation
TLPH SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Talphera, Inc.. (CIK: 0001427925)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Apr 3, 2026 | 4 | xslF345X06/form4-04032026_100412.xml | View → |
| Apr 3, 2026 | 4 | xslF345X06/form4-04032026_100414.xml | View → |
| Apr 3, 2026 | 4 | xslF345X06/form4-04032026_100457.xml | View → |
| Apr 3, 2026 | 4 | xslF345X06/form4-04032026_100455.xml | View → |
| Mar 25, 2026 | 4 | xslF345X06/form4-03252026_110351.xml | View → |
❓ Frequently Asked Questions about TLPH
What is the AI rating for TLPH?
Talphera, Inc.. (TLPH) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are TLPH's key strengths?
Claude: Strong liquidity position with 5.49x current ratio and 5.18x quick ratio. Conservative leverage with 0.34x debt-to-equity ratio.
What are the risks of investing in TLPH?
Claude: Negligible revenue base of $28K annually with massive -$13.5M operating loss. Critical cash burn of -$11.4M operating cash flow providing only ~6 month survival runway.
What is TLPH's revenue and growth?
Talphera, Inc.. reported revenue of $28.0K.
Does TLPH pay dividends?
Talphera, Inc.. does not currently pay dividends.
Where can I find TLPH SEC filings?
Official SEC filings for Talphera, Inc.. (CIK: 0001427925) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is TLPH's EPS?
Talphera, Inc.. has a diluted EPS of $-0.10.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is TLPH a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Talphera, Inc.. has a STRONG SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is TLPH stock overvalued or undervalued?
Valuation metrics for TLPH: ROE of -83.9% (sector avg: 15%), net margin of -51,035.7% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy TLPH stock in 2026?
Our dual AI analysis gives Talphera, Inc.. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is TLPH's free cash flow?
Talphera, Inc..'s operating cash flow is $-11.4M, with capital expenditures of $0.0. FCF margin is -40,585.7%.
How does TLPH compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -51,035.7% (avg: 12%), ROE -83.9% (avg: 15%), current ratio 5.49 (avg: 2).